SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
VANCOUVER, British Columbia, April 09, 2018 -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (OTCQB:RVVQF) (Frankfurt:1IT) today announced that it has secured DTC Eligibility for its common shares listed on the OTC market in the United States.
About the Depository Trust Company
The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
“George Robinson”
Chief Executive Officer
For further information, please contact:
Mathieu McDonald, Corporate Communications – 604-484-1230
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
